Clinical Research Directory

Inclusion Criteria: For prostate cancer patients: * Patients histologically proven prostate adenocarcinoma * Prostate specific antigen (PSA) obtained within three months prior to enrollment * Localised prostate cancer at any stage eligible for radiotherapy: i.e. any T- or Gleason stage, but no pelvic lymph nodes can be included within the target to be treated * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Ability to understand and the willingness to sign a written informed consent document. * Hypofractionated radiation therapy (HYPO) fractionated patients with a prescribed dose of 42.7Gy in 7 fractions. * MRIOnly workflow meaning synthetic generated CT based on Magnetic resonance imaging (MRI) * Patients over 40 years old For lung cancer patients: * Lung cancer or localised metastatic disease from other cancer diagnoses, accepted for stereotactic radiotherapy to 45Gy in 3 fractions * Lesion distinguishable on Computer Tomography and where the majority of adjacent tissue is the lung. * Ability to understand and the willingness to sign a written informed consent document. * Is able to perform treatment simulation Exclusion Criteria: For prostate cancer patients: * Patient must have three gold fiducial markers inserted in the prostate * Patients with artificial Hip(s), lumbar spinal surgical rods or other large metallic pelvic implants * Patients with overlapping implanted gold fiducials in X-ray imaging * Unfeasible to track fiducials with kv imaging/existing online imaging systems For lung cancer patients: * Previous treatment with radiotherapy for lung cancer or lung metastasis * Idiopathic lung fibrosis